Tag: autism spectrum disorder

Since 2010, There Have been Major Shifts in Medical Profiles of Adults Diagnosed with Autism

Pronounced shift from prior diagnosis of epilepsy, psychosis, intellectual disability to ADHD, anxiety, depression
Steep rise in diagnoses among 16-20 year olds, females, and those of White ethnicity

Photo by Alex Green on Pexels

The medical profiles of adults diagnosed with autism have changed hugely since 2010, finds a study of medical records in the UK and Sweden, published in the online journal BMJ Mental Health.

There’s been a pronounced shift from a prior diagnosis of epilepsy, psychosis and intellectual disability to ADHD (attention deficit hyperactivity disorder), anxiety, and depression since 2010, the data analysis indicates.

And the steepest rise in diagnoses has been among 16-20 year olds, females, and those of White ethnic background.

The number of people being diagnosed with autism has increased worldwide in recent decades, although it’s not entirely clear if this has been driven by greater public awareness, reduced stigma, or changes in diagnostic practice, say the researchers.

To explore this further, the researchers studied UK primary care records up to 2023 (CPRD Aurum; 47 413 279 patients from 1784 general practices) and Swedish population-wide registry data (13 345 950 people) up to 2021 to look at trends over time.

They particularly wanted to find out if the social and demographic patterns of incident and prevalent autism diagnoses in adults, and the prevalence of other concurrent neuropsychiatric conditions, have changed over time. They also wanted to know if these trends are consistent in direction and magnitude across both the UK and Sweden.

Eligibility criteria included study entry on 1 January 2010, 16 years of age and, in the UK, at least 1 year registered at a general practice. Monitoring ended at death, ceasing to be registered at a general practice (UK), emigration (Sweden), or study end date (31 December 2023 in the UK and 31 December 2021 in Sweden), whichever came first.

The data were analysed for each person’s first recorded diagnosis of: autism; intellectual disability; ADHD; epilepsy; migraines/headaches; anxiety; depression; psychosis; bipolar disorders; obsessive-compulsive disorder and related conditions; stress-related conditions (including post-traumatic stress disorder); eating disorders; personality disorders; suicidality/self-harm; sleep disorders; and chronic fatigue.

First recorded prescriptions (UK) or dispensations (Sweden) of antipsychotics; antidepressants; antiseizure medications; opioids; gabapentinoids; melatonin and benzodiazepines/z-drugs (sedatives) were also noted.

In the UK, 24 537 039 adults contributed to the study, 141 119 of whom had been diagnosed with autism. In Sweden, 9 096 874 adults contributed, 100, 817 of whom had been diagnosed with autism.

Incident (first recorded) autism diagnoses in adults were consistently higher in Sweden than in the UK, but the number of new cases rose sharply in the UK after 2020.

In the UK, rates of new diagnoses increased from 6/100 000 people in 2010 to 64 in 2023. In Sweden, they rose from 43/100 000 people in 2010 to 65 in 2021.

New diagnoses increased fastest for 16–20 year-olds in both nations, rising from 31/100 000 people in 2010 in the UK to 364 in 2023, and from 165/100 000 people in 2010 in Sweden to 361 in 2021.

New diagnoses also rose fastest in females in both nations, as well as in people of White ethnicity in the UK and those with Swedish-born parents in Sweden.

In both countries, age-standardised prevalence was consistently higher for males than females, increasing in both sexes over the study period to 1.4% for males and 0.7% for females in the UK in 2023, and to 1.8% for males and 1.2% for females in Sweden in 2021.

Prevalence also increased over time in all age groups and was consistently higher in younger age groups. The prevalence of autism among 16–20 year-olds was 4.1% in 2023 in the UK and in Sweden in 2021.

Over time, the proportion of adults with autism who had a prior diagnosis of epilepsy, psychosis, and/or intellectual disability fell while the proportion of those with a prior diagnosis of ADHD, anxiety, depression, and other mental illnesses increased.

For example, in the UK between 2010 and 2023, a history of epilepsy among adults with newly diagnosed with autism fell from 10% to 4%, while a history of anxiety rose from 29% to just over 58%. Trends were broadly consistent between both sexes.

This is an observational study, and as such, can’t establish the reasons for the observed changes in the profiles of those diagnosed with autism.

But point out the researchers: “The characteristics of individuals diagnosed as autistic have changed dramatically since 2010 in both the UK and Sweden.”

And they conclude: “While these data are unable to shed light on whether these changes indicate greater appreciation of nuanced forms of autism, or misdiagnoses of other psychiatric presentations as autism, efforts will need to be made to recognise and address the needs with appropriate support.”

Source: The BMJ Group

‘Microexons’ Linked to Autism Cases Without a Genetic Basis

Source: Pixabay CC0

New research from scientists at King’s College London, the University of Toronto, the Sloan Kettering Institute and the Francis Crick Institute advances understanding of the genetics of autism spectrum disorder (ASD).

In a study published in Nature, researchers identified hundreds of new microexons – short gene segments that appear to play a key role in ASD and other neurological conditions – and developed a machine-learning approach to predict the impact of ASD-associated genetic variants on the regulation of these segments.

Autism is characterised by multifactorial genetics. Hundreds of genomic variants have been associated with autism, and these deliver a genetic diagnosis in 15 per cent of people with autism diagnoses.

Dr Benjamin Blencowe, King’s College London and University of Toronto

That means that for 85 per cent of people with an ASD diagnosis, a genetic link is unknown. Dr Benjamin Blencowe, the study’s co-senior author, believes that many contributing genetic factors may have remained undetected because they occur in regions of the genome that do not have a known function.

The genomic regions surrounding microexons are one such example. Through alternative splicing, these very short snippets of DNA – which range from three to 27 DNA “letters” long – can be included or excluded from the messenger RNA instructions used to make proteins. The resulting proteins vary slightly in composition yet contribute to a greater diversity of critical protein functions.

In the newly published study, Dr Guillermo Parada, the study’s co-lead author and a postdoctoral fellow at King’s College London and the Francis Crick Institute, used a computational tool he developed called MicroExonator to analyse over 100 terabytes – enough storage for 25 million smartphone photos – of publicly available RNA sequencing data. He identified more than 1500 new microexons, of which nearly 300 appeared to be specifically spliced in the brain.

The researchers also observed that many of the newly discovered microexons are concentrated in genes associated with critical brain-specific processes, further supporting the idea that these tiny DNA fragments contribute to neurological function.

The researchers then asked whether DNA variants found in the genome of people with autism might preferentially impact the expanded repertoire of microexons.

To answer that question, Dr Parada and study co-lead author and postdoctoral fellow Dr Hannes Bretschneider teamed up with Dr Quaid Morris, a faculty member at Memorial Sloan Kettering Cancer Center and Vector Institute and co-senior author on the study, to build and apply a machine-learning model that identifies the key regulatory features governing whether a microexon is spliced in or out of messenger RNAs. This so-called regulatory code encompasses specific sequences of DNA letters flanking microexons.

What surprised me was that the sequences the model identified as important closely matched those conserved throughout vertebrate evolution.

Dr Guillermo Parada, King’s College London and the Francis Crick Institute

DNA sequences that are highly conserved, or the same, between species generally have critical functions.

Through a collaboration with Dr Stephen Scherer and Brett Trost, both scientists at The Hospital for Sick Children and professors of molecular genetics at Temerty Medicine, the researchers applied their model to whole-genome sequence data from thousands of people with autism and neurotypical sibling pairs, and analysed the predicted impact of ASD-associated genetic variants on the microexon regulatory code.

Using our model, we were able to show that rare genetic variants generally have the largest predicted effects on the splicing of neuronal microexons.

Dr Benjamin Blencowe

The model further pinpointed a subset of rare variants predicted to alter microexon splicing that are associated with autism. The research team also found that the variants predicted to affect microexons are predominantly detected among the 85 per cent of people with an autism diagnosis previously lacking a genetic link to autism.

These new findings build on over a decade of research from the Blencowe lab to uncover the role of microexons in ASD, including earlier work showing that microexons are frequently misregulated in the brains of people with autism and that mice lacking microexon splicing display multiple ASD-like behaviours.

“In terms of future work, it will be important to understand how disrupted microexons affect interactions between proteins that are important for nervous system development and function,” says Dr Blencowe. One of the research programmes in his lab is also exploring new therapeutic approaches to target microexon dysregulation.

Dr Blencowe says that beyond helping to define some of the missing genetics of ASD, their study provides a valuable resource to advance research in the field.

The researchers believe that the machine-learning model they developed can be used to characterise newly discovered genetic variants and their effects in other neurological conditions, like schizophrenia and epilepsy, where microexons are believed to play a role.

This story has been adapted from a version that appears on the University of Toronto website.

Source: King’s College London

Autism Is Linked to 14-Year Deficit in Life Expectancy

Excess mortality from influenza, malnutrition, pneumonitis, drowning, and pneumonia contributes to the life expectancy gap

Photo by Peter Burdon on Unsplash

People with autism spectrum disorder (ASD) in the United States face a 14-year deficit in life expectancy, finds a study published in JAMA Network Open. The study provides one of the first large-scale estimates of age-specific death rates and life expectancy among people with ASD.

Autism research has historically focused on biology, genetics, environmental risk factors, and diagnosis, with less attention to long-term health outcomes, crucial for understanding the natural history of the disorder and for developing intervention programs. The new findings, from researchers at Columbia University Mailman School of Public Health and the University of Colorado Anschutz, highlight substantial disparities in life expectancy and identify causes of excess mortality that may be preventable.

“Autism is a complex lifelong condition with substantial costs to the US healthcare system,” said Guohua Li, DrPH, MD, professor of Epidemiology at Columbia Mailman School. “Elevated mortality risk in people with ASD has been reported since the late 1980s, but life expectancy for the autistic population remained unknown because of inadequate data on age-specific death rates.”

To examine life expectancy and causes of excess mortality, the researchers analysed data from the Transformed Medicaid Statistical Information System and Children’s Health Insurance Program Statistical Information System. The enhanced Medicaid data include mortality information linked to the National Death Index for beneficiaries in all 50 states and the District of Columbia from 2000 through 2020.

During the 21-year study period, 2 048 046 individuals with ASD were enrolled in Medicaid. Of these, 76 percent were male; 49 percent were non-Hispanic White, 15 percent were non-Hispanic Black, and 17 percent were Hispanic. A total of 18 268 Medicaid beneficiaries with ASD died between 2000 and 2020.

Life expectancy at birth for Medicaid beneficiaries with ASD was 64.9 years –5.6 years shorter than for the overall Medicaid population and 13.8 years shorter than for the U.S. general population. Estimates were broadly similar across sex and racial and ethnic groups, although the gap relative to the general population was greater for women than for men.

Life expectancy among Medicaid beneficiaries with ASD increased by 1.7 years during the study period, from 63.9 years in 2000–2004 to 65.6 years in 2015–2019. However, the gap compared with both the broader Medicaid population and the U.S. general population persisted.

Medicaid beneficiaries with ASD had a 44 percent higher mortality risk than other Medicaid beneficiaries. Excess mortality occurred across most categories of diseases and health conditions, with particularly heightened risk from influenza, malnutrition, pneumonitis, non-transport accidents, drowning, and pneumonia.

The researchers also found that, compared with the general population, autistic women experienced a greater life expectancy deficit than autistic men, largely associated with higher rates of psychiatric comorbidities and related excess mortality.

“Life expectancy for the autistic population enrolled in Medicaid in the United States is about 65 years, which is the same as for the general population in Haiti or Angola,” said Carolyn DiGuiseppi, MD, PhD, professor of epidemiology at Colorado School of Public Health. “This finding is sobering.”

“The good news is that much of the excess mortality among people with ASD is avoidable through improved social support, primary care, and home- and community-based services,” Said Li, who is also professor of anaesthesiology at Vagelos College of Physicians and Surgeons.

Source: Columbia Mailman School of Public Health

Study Finds Unexpected New Target to Treat Autism Symptoms

Photo by Peter Burdon on Unsplash

Researchers at The Ottawa Hospital and the University of Ottawa were able to reverse certain behavioural symptoms in a mouse model of autism by fixing a problem in the brain blood vessels. Their findings, published in Neuron, present a promising new treatment target for these symptoms.

Autism is a neurodevelopmental condition with widely varying characteristics. Some of the behavioural symptoms can make life more challenging. While many people with autism have found ways to manage these symptoms, no drug treatment exists. 

“The road from discovery to clinical trials is long, but we’re excited by the possibility that our findings might one day improve the daily lives of people with autism,” said senior author Dr Baptiste Lacoste, senior scientist at The Ottawa Hospital and professor at the University of Ottawa. 

Dr Lacoste’s team previously discovered that blood vessels in the brain don’t work properly in mouse models with a 16p11.2 deletion, one of the most common genetic mutations seen in autism. They were the first to look at what was happening in the blood vessels of the brain. 

The researchers found the problem began in cells lining the blood vessels, called the endothelial cells. These cells make sure blood quickly gets to the parts of the brain that are active. This responsive blood supply is needed for proper brain function. 

However, the endothelial cells in these mice don’t respond quickly enough. This happens early in brain development and causes behavioral symptoms later in life, including hyperactivity, repetitive movements, and motor learning impairment.

In this new study, driven by former PhD student Dr Julie Ouellette, the research team looked at what was wrong with these endothelial cells and whether it could be fixed. 

The team led by Dr Lacoste found that the endothelial cells had half the normal level of a molecule called ATP. ATP is usually considered an energy molecule, but in this case the cell was missing its target, called a P2Y2 receptor, on its surface. 

By activating this P2Y2 receptor, the researchers could restore the cell’s function, increase blood flow in the brain and reverse the behavioral symptoms in adult mice. This was achieved using a drug known to activate P2Y2 and currently approved for humans in Japan and South Korea to treat dry eye syndrome. 

“It’s as if these cells are asleep, and now we can wake them up,” says Dr Lacoste. “And we may only need to treat them once to wake them up permanently. We will test that further, but it’s an encouraging feature for a future treatment.” 

This study only looked at adult mice. This means targeting P2Y2 could reverse behavioural symptoms that were already well established.  Next, the team plans to treat mice earlier in life to see if early treatment has additional benefits. 

The team has also filed a patent application for using P2Y2 activation in the blood vessels to treat autism symptoms. They are interested in exploring drug development with the aim of eventual clinical trials.

Source: University of Ottawa

Rare Pregnancy Infections Linked to Autism

Photo by Anna Hecker on Unsplash

Infections that, in rare cases, can be transmitted from the pregnant woman to the foetus are linked to an increased risk of autism and intellectual disability in the child. This is shown by a study from the Karolinska Institute published in JAMA Pediatrics.

”It is important to emphasise that it is unusual for these infections to be transmitted from mother to child. They account for a very small proportion of all cases of autism in the population, but for those children who are actually affected, we see a clearly elevated risk of both autism and intellectual disability,” says Reneé Gardner, a researcher at the Department of Global Public Health at Karolinska Institutet, who contributed to the study. 

The researchers have investigated how so-called TORCH infections affect children’s later development. TORCH is a group of infections that can be transmitted from a pregnant woman to the foetus and includes, amongst others, cytomegalovirus, rubella, toxoplasma and herpesvirus. Unlike many common infections, these pathogens can sometimes cross the placenta and directly infect the foetus.

Were followed for three decades

The study included 3.7 million people born in Sweden between 1987 and 2021. Of these, 975 had been diagnosed with a congenital TORCH infection. The researchers followed the participants for up to three decades to investigate whether the infections were linked to later diagnoses and educational outcomes.

The results show that children with a congenital TORCH infection were approximately three times more likely to be diagnosed with autism later in life and more than seven times more likely to be diagnosed with an intellectual disability compared with children without the infection. The risk of severe to profound intellectual disability was up to 30 times higher.

However, despite the high relative risks, the significance of these infections at a population level is limited, as they are rare in newborns. The researchers estimate that congenital TORCH infections may be linked to approximately 1.2 per cent of all cases of severe intellectual disability, whilst around 0.034 per cent of all cases of autism in Sweden can be explained by these infections. They also estimate that approximately one in five children born with a TORCH infection may later develop autism.

”It has long been known that these infections can cause intellectual disability. However, the link to autism has been less clear in previous research, which has often been based on small patient groups. This study is the largest to date in this field and is based on national register data covering almost the entire population of Sweden,” says Hugo Sjöqvist, a PhD student and lead author of the study.

To better determine whether the associations were due to the infections themselves, the researchers also compared children who had had a TORCH infection with their own siblings who had not had the infection. The results were similar in the sibling comparisons, which suggests that the associations cannot be explained solely by factors shared within families.

The researchers found no clear links between TORCH infections and other neuropsychiatric conditions, such as ADHD or obsessive-compulsive disorder. However, an impact on academic performance was observed. Even children who had not been diagnosed with autism or an intellectual disability had, on average, lower grades than their peers without the infection.

“Our results suggest that certain infections transmitted to the foetus during pregnancy may have long-term effects on brain development. Although these congenital infections are rare, some of them can be prevented, which makes them important from a public health perspective,” says Reneé Gardner.

The researchers particularly emphasise the importance of preventive measures. For example, the study points out that rubella has virtually disappeared in Sweden following the introduction of national vaccination programmes. According to the researchers, the results underline the importance of maintaining vaccination programmes and other strategies to prevent infections that can be transmitted from the pregnant woman to the foetus.

The research was funded by the Swedish Research Council. Co-author David Mataix-Cols states that he has received author’s fees from UpToDate Inc and that he is a partner in Scandinavian E-Health AB, which is unrelated to the publication.

Publication

”Congenital TORCH infections and neurodevelopmental outcomes: A population- and sibling-based cohort study”, Hugo Sjöqvist, Christina Dalman, David Mataix-Cols, Reneé M Gardner, Håkan Karlsson. JAMA Pediatrics, online 21 September 2026, doi: 10.1001/jamapediatrics.2026.4229.

Facts on how TORCH infections can be prevented

• T = Toxoplasma: Avoid raw or undercooked meat, wash vegetables, and take care when handling cat faeces. 

• O = Other (including infections such as syphilis): Screening during pregnancy and antibiotic treatment. 

• R = Rubella: Vaccination before pregnancy (MMR vaccine). 

• C = Cytomegalovirus (CMV): Good hand hygiene; avoid contact with young children’s saliva and urine. 

• H = Herpes simplex (HSV): Identification and treatment of infection during pregnancy; sometimes a caesarean section is performed in the event of active genital herpes prior to delivery.

Source: Karolinska Institutet

Autistic Kids Showed Improved Social Skills After Summer Programme

Photo by Peter Burdon on Unsplash

A summer intervention programme for autistic children ages 4-6 with no intellectual disability significantly improved their social performance, according to a study by researchers at the Institute for Autism Research (IAR) at the University at Buffalo. It was published in Advances in Neurodevelopmental Disorders.

“Completion of our 5-week summerMAXyc programme was associated with significant social, behavioral and autism symptom benefits for the children,” says Christopher J. Lopata, PsyD, co-author on the study and co-founder/co-director of the IAR with Marcus L. Thomeer, PhD; both are professors of pediatrics in the Jacobs School of Medicine and Biomedical Sciences at UB. “Developing such foundational skills early in development sets the stage for development of more advanced skills later in childhood, adolescence and adulthood, thus leading to better long-term outcomes.”

Thomeer notes that while programmes for autistic children with no intellectual disability ages 4-6 do exist, few provide intensive social programming. This population also tends to engage in significantly fewer group recreational activities in general than their peers without autism, further limiting social development opportunities.

“This constitutes a significant gap in social intervention development and service provision, which prompted our interest in developing such a programme for this population,” he says. 

Five weeks, five days a week

The intensive summerMAXyc programme was conducted five-days-a-week over five weeks in the summer. The programme follows a similar model to that of the IAR’s successful, evidence-based summerMAX programme for older children, which has helped improve the social skills of hundreds of children since it began 23 years ago.

In the summerMAXyc programme, each 6-hour day included 8 cycles of 30 minutes each, which began with 10 minutes of instruction in particular skills, such as having a conversation or accepting consequences, followed by a 20-minute cooperative activity.

According to the study, the children found that the programme was fun and helped them learn skills and make new friends. Average child satisfaction was 14.9 out of a possible 15 with parent satisfaction at 69.8 out of a possible 70. Parents reported significant improvement in the children’s social skills, behaviors and autism symptoms.

There is broad consensus that earlier intervention is associated with better outcomes for autistic children. And parents are often the first to recognize the need.

“Parents reach out to us because their child has difficulty navigating the social world,” says Thomeer. “They describe their autistic children as wanting to have friends but not knowing what to do in social situations.”

Families noticed the difference

Over the course of their child’s participation in summerMAXyc, Thomeer says, parents reported that other family members began to notice the child playing with others, not just playing alone. They also noticed that the child now makes eye contact, asks about others, plays games without getting upset and can recognise and understand different emotions.

According to Thomeer, a mother of one of the participants reported that her child not only noticed that she was frustrated about something, but also told her to “squeeze the orange,” a technique the children are taught where they squeeze an imaginary orange and take a deep breath in order to calm themselves down.

One of the study’s major strengths involved the use of objective observers to assess the children’s social performance. According to Lopata, parents are a critical source of information, however there is a risk of bias because they know that their children are in the intervention. Most social skills intervention studies for autistic children rely on parent ratings alone and therefore suffer from this limitation, he adds.

 “Our use of masked observers – trained individuals – eliminated that risk because they were unaware that the children received an intervention,” says Lopata.

The authors also note that the intervention was similarly successful in improving the children’s social performance and autism features regardless of the child’s age, IQ level, communication ability or level of diagnostic symptoms.

“There is widespread recognition in the field that no intervention will be effective for all autistic children and there is a significant need to determine which children are most likely to benefit from a specific intervention,” says Lopata. “Answering this question can help ensure that scarce resources are efficiently allocated and that children receiving a given intervention are most likely to benefit.”

The next step is to test the intervention in a large-scale randomised clinical trial with a control group, which would be a first for such a social intervention in this population. 

Original written by Ellen Goldbaum

Source: University at Buffalo

Can Sports Help Improve Motor Skills in Children with Autism?

Photo by Thao LEE on Unsplash

Research suggests that more than half of children with autism spectrum disorder, a neurodevelopmental condition, experience motor impairments. An analysis in Developmental Medicine & Child Neurology indicates that sports-based interventions may improve motor skills in children with autism spectrum disorder, with martial arts and aquatic training demonstrating the most consistent benefits.

The analysis was based on data from 11 clinical trials of various sports. Martial arts demonstrated consistently large improvements in balance, total motor skills, and object control skills, with especially strong effects in Tai Chi Chuan and kata programs. Aquatic training demonstrated large improvements across balance, locomotor skills, and object control skills. Gymnastics and trampoline interventions demonstrated large improvements in balance and bilateral coordination, with additional effects on total motor scores in trampoline studies. Table tennis produced broad gross motor improvements, and Australian football had a large effect on object control skills and had a medium effect on balance and total motor skills. Across all sports categories, balance was the most consistently improved motor domain.

The authors noted that many of the studies had significant limitations, however, and higher-quality studies are needed.

“Organized sports-based interventions may offer benefits beyond recreation for children with autism by supporting motor skill development,” said corresponding author Sonia Khurana, PT, PhD, of Old Dominion University. “While our review identified promising effects, particularly for martial arts and aquatic training, larger and more rigorous studies are needed to confirm these benefits and guide evidence-based recommendations.”

Source: Wiley

Certain Mental Disorders Are Associated with Faster Brain Ageing

Increased brain ageing was associated with dementia, addiction and psychiatric disorders like schizophrenia

Generated with Gencraft AI

People with dementia, mild cognitive impairment, alcohol addiction, or psychiatric disorders such as schizophrenia show increased brain ageing, each in specific patterns within the brain, according to a study published July 21st in the open access journal PLOS Medicine by Shile Qi from the Nanjing University of Aeronautics and Astronautics, China, and colleagues.

Some conditions can make the brain age faster. Scientists calculate how old the brain is relative to the body using the predictive age difference (PAD), the difference between chronological age and the age predicted by brain imaging, where a positive PAD indicates that ageing is accentuated or increased. To better understand how brain disorders and divergences might affect brain ageing, the authors of this study collected structure magnetic resonance imaging (MRI) data from 45 900 controls across several brain imaging banks, and compared them with those of 2698 patients with different brain conditions and differences, including attention-deficit/hyperactivity disorder (ADHD), autism spectrum disorder (ASD), alcohol or tobacco addiction, Alzheimer’s disease (AD), mild cognitive impairment (MCI), schizophrenia, bipolar disorder or major depressive disorder.

The authors found that neurodegenerative disorders of AD and MCI had the largest association with a high PAD. Addiction and psychiatric disorders were also associated with increased PAD. In contrast, there were no differences in PAD between people with ADHD or ASD and controls.

The researchers also looked at PAD values in specific areas of the brain, and examined which genes showed increased expression in people with different brain conditions. The prefrontal cortex showed higher PAD across brain disorders. Higher PAD in the frontal and temporal lobes was associated with psychiatric disorders, while high PAD in the frontal and occipital cortex was associated with dementia. Addiction was connected with high PAD in the default mode network, and in the salience network and the putamen and thalamus. There were also differences in gene transcription that associated with specific conditions and divergences. While the results are correlational, and not causal, and while some conditions such as psychiatric disorders and addiction have high co-occurrence, the author suggest that understanding more about PAD could help provide biomarkers for commonly occurring brain disorders.

The authors add, “Different neurological disorders appear to leave different signatures on the brain ageing clock, which may help researchers better understand the neural and biological pathways involved in these conditions.”

Provided by PLOS

A New Diagnosis of ‘Profound Autism’ Is on the Cards. Here’s What Could Change

Kelsie Boulton, University of Sydney; Marie Antoinette Hodge, University of Sydney, and Rebecca Sutherland, University of Sydney

Photo by Peter Burdon on Unsplash

When it comes to autism, few questions spark as much debate as how best to support autistic people with the greatest needs.

This prompted The Lancet medical journal to commission a group of international experts to propose a new category of “profound autism”.

This category describes autistic people who have little or no language (spoken, written, signed or via a communication device), who have an IQ of less than 50, and who require 24-hour supervision and support.

It would only apply to children aged eight and over, when their cognitive and communication abilities are considered more stable.

In our new study, we considered how the category could impact autism assessments. We found 24% of autistic children met, or were at risk of meeting, the criteria for profound autism.

Why the debate?

The category is intended to help governments and service providers plan and deliver supports, so autistic people with the highest needs aren’t overlooked. It also aims to re-balance their under-representation in mainstream autism research.

This new category may be helpful for advocating for a greater level of support, research and evidence for this group.

But some have raised concerns that autistic people who don’t fit into this category could be perceived as less in need and excluded from services and funding supports.

Others argue the category doesn’t sufficiently emphasise autistic people’s strengths and capabilities, and places too much emphasis on the challenges that are experienced.

What did we do?

We conducted the first Australian study to examine how the “profound autism” category might apply to children attending publicly funded diagnostic services for developmental conditions.

Drawing on the Australian Child Neurodevelopment Registry, we examined data from 513 autistic children assessed between 2019 and 2024. We asked:

  • how many children met the criteria for profound autism?
  • were there behavioural features that set this group apart?

Because we focused on children at the time of diagnosis, most (91%) were aged under eight years. We described these children as being “at risk of profound autism”.

What did we find?

Around 24% of autistic children in our study met, or were at risk of meeting, the criteria for profound autism. This is similar to the proportion of children internationally.

Almost half (49.6%) showed behaviours that were a safety risk, such as attempting to run away from carers, compared with one-third (31.2%) of other autistic children.

These challenges weren’t limited to children who met criteria for profound autism. Around one in five autistic children (22.5%) engaged in self-injury, and more than one-third (38.2%) showed aggression toward others.

So, while the category identified many children with very high needs, other children who didn’t meet these criteria also had significant needs.

Importantly, we found the definition of “profound autism” doesn’t always line up with the official diagnostic levels which determine the level of support and NDIS funding children receive.

In our study, 8% of children at risk of profound autism were classified as level 2, rather than level 3 (the highest level of support). Meanwhile, 17% of children classified as level 3 did not meet criteria for profound autism.

Our concern

We looked at children when they first received an autism diagnosis. Children were aged 18 months to 16 years, with more than 90% under the age of eight years.

This aligns with our earlier research, showing the average age of diagnosis in public settings is 6.6 years.

From a practical perspective, our biggest concern about the profound autism category is the age threshold of eight years.

Because most children are already assessed before age eight, introducing this category into assessment services would mean many families would need repeat assessments, placing additional strain on already stretched developmental services.

Second, modifications will be needed if this criteria is going to be used to inform funding decisions as it didn’t map perfectly onto level 3 support criteria.

On balance, however, our results suggest the profound autism category may provide a clear, measurable way to describe the needs of autistic people with the highest support requirements.

Every autistic child has individual strengths and needs. The term “profound autism” would need to be promoted with inclusive and supportive language, so as to not replace or diminish individual needs, but to help clinicians tailor supports and obtain additional resources when needed.

Including the category in future clinical guidelines, such as the national guideline for the assessment and diagnosis of autism, could help ensure governments, disability services and clinicians plan and deliver supports.

What can you do in the meantime?

If you’re concerned your child requires substantial support, here are some practical steps you can take to ensure their needs are recognised and addressed:

Explain your concerns

Not all clinicians have experience working with children with high support needs. Be as clear as possible about behaviours that affect your child’s safety or daily life, including self-injury, aggression or attempts to run away. These details, while difficult to share, help give a clearer picture of your child’s support needs.

It can also be a challenge to find and access clinicians with appropriate expertise. Another potential benefit of having a defined category is that it can better help families navigate care.

Ask about support for the whole family

Our studies show that many caregivers want more support for themselves but don’t always ask. Talk with clinicians about supports for yourself as well, including respite, or family support groups.

Reach out

Coming together with other carers and families can reduce your own isolation and normalise many of the unique challenges you face. Connecting with like-minded people can provide a supportive, empathetic and empowering community.

Plan for safety

For children with high support needs, prioritise safety planning with your child’s care team. This can include strategies to reduce risks, as well as planning how best to support your child’s interactions with health, education and disability services over time.

Kelsie Boulton, Senior Research Fellow in Child Neurodevelopment, Brain and Mind Centre, University of Sydney; Marie Antoinette Hodge, Clinical Lecturer, University of Sydney, and Rebecca Sutherland, Lecturer & Speech Pathologist, University of Sydney

This article is republished from The Conversation under a Creative Commons license. Read the original article.

Leucovorin Prescriptions in US for Children with Autism Surged After Public Attention

National study found use of the drug rose sharply following major media coverage and later White House promotion, despite limited large-scale evidence for autism treatment

Leucovorin prescriptions for children with autism rose more than 2000% by late 2025. Courtesy of UC San Diego Health Sciences.

Researchers from the University of California San Diego found that prescriptions for leucovorin, a drug sometimes used off-label for autism spectrum disorder (ASD), rose sharply among children after widespread media attention and public statements from White House officials. The study, published May 18, 2026 in JAMA Network Open, analysed national electronic health record data and found prescribing rates increased more than 2000% compared with prior years.

“Families of children with autism are often searching for therapies that might improve communication and quality of life, especially when treatment options are limited,” said Joshua Rothman, MD, clinical assistant professor of pediatrics at the UC San Diego School of Medicine and first author of the study. “What this study shows is how quickly information shared through news coverage, social media and public figures can influence real-world prescribing patterns, even before large clinical trials establish whether a treatment is truly safe and effective for broad use.”

Leucovorin, also known as folinic acid, is a biologically active form of folic acid. Small clinical trials have suggested that some children with autism and folate-related deficiencies may experience improvements in verbal communication after taking the medication. However, researchers note that large-scale studies confirming the drug’s effectiveness and long-term safety for children with ASD have not yet been completed.

To better understand prescribing trends, the researchers analysed records from the Epic Cosmos database, which includes more than 300 million patient records from over 1800 hospitals and 41 500 clinics across all 50 states and Washington, D.C. The study focused on 838 801 children with autism who accounted for more than 11.9 million outpatient encounters between January 2023 and January 2026.

For roughly two years, leucovorin prescribing rates remained relatively stable, averaging about 34 prescriptions per 100 000 outpatient encounters among children with autism. Rates then began climbing steadily in early 2025 before surging later that year. By August 2025, prescribing rates had risen to 335 prescriptions per 100 000 encounters. In November 2025, rates climbed again to more than 835 prescriptions per 100,000 encounters.

The researchers observed that the initial rise in prescribing coincided with a February 2025 national television news segment featuring a family who reported dramatic language improvements in their child after treatment with leucovorin. Interest in the medication expanded further after White House officials publicly promoted leucovorin in September 2025 as part of broader autism-related initiatives.

“Families of children with autism are often searching for therapies that might improve communication and quality of life, especially when treatment options are limited. What this study shows is how quickly information shared through news coverage, social media and public figures can influence real-world prescribing patterns, even before large clinical trials establish whether a treatment is truly safe and effective for broad use.”

— Joshua Rothman, MD, clinical assistant professor of paediatrics at the UC San Diego School of Medicine and first author of the study

“The timing was striking,” Rothman said. “The increases began after a widely viewed media story and accelerated again after federal officials publicly discussed the medication. It highlights how rapidly clinical practice can shift when a treatment captures public attention.”

The study does not determine whether leucovorin improves symptoms of autism, nor does it evaluate patient outcomes after treatment. Researchers also cautioned that prescriptions recorded in the database could not always be linked to a confirmed medical indication.

Still, the authors say the rapid increase in use raises important questions for clinicians, policymakers and families. In March 2026, the US Food and Drug Administration approved leucovorin for cerebral folate transport deficiency, an ultra-rare genetic neurological disease associated with specific genetic changes, but the drug was not approved for autism spectrum disorder.

Researchers say the findings underscore the need for continued monitoring of prescribing trends and for larger randomised clinical trials evaluating whether leucovorin is beneficial for specific groups of children with autism.

“We now have a real-world example of how public attention can accelerate adoption of a therapy before the evidence fully catches up,” Rothman said. “The next step is making sure we generate the rigorous data needed to help families and clinicians make informed decisions.”

Read the full study: Rates of Leucovorin Prescriptions for Children With Autism

Source: University of California – San Diego